AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...